We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Whistleblower Apologizes for Error in Lawsuit Against Unilife

Whistleblower Apologizes for Error in Lawsuit Against Unilife

August 21, 2015

York, Pa.-based Unilife has scored a big win after a whistleblower acknowledged that he was wrong in alleging the company failed to comply with FDA requirements.

Talbot (Todd) Smith made the admission in a federal court in Philadelphia Aug. 18, nearly three years to the day after bringing suit against Unilife. He had accused the company of retaliatory termination for disclosing protected disclosures related to shareholder fraud and noncompliance with FDA requirements.

“I now understand that there were no violations of FDA regulations during my tenure at Unilife,” Smith said during the dismissal of the suit, according to a Unilife release.

“In addition, in the summer of 2011, Unilife issued press releases, which stated that they had begun shipments of validated Unifill product to customers. I now understand that the production process was, in fact, validated.”

Validation Suspicions

Smith served as vice president of integrated supply chain at Unilife from September 2011 through August 2012. In his amended complaint, Smith alleged that the company had lured him to join with false assertions that the Unifill prefilled syringe had been validated and that shipments had been made to Sanofi, which had acquired exclusive rights to negotiate the purchase of the product in 2008.

However, despite company press releases in the summer of 2011 saying shipments and sales of the product had begun, Smith alleged that the required FDA validation process was not completed until March 30, 2012. That meant the company either was shipping products before they were validated or it was shipping samples and not making the sales it had claimed in the press releases.

Smith became increasingly concerned, airing his misgivings to his supervisor, Ramin Mojdeh. Rather than listen to his concerns, Mojdeh allegedly told Smith he “was following the rules and procedures established by the FDA too closely,” and thus slowing down production.

Undeterred, Smith kept making complaints and, in one instance, opened a CAPA when unreleased product was allegedly shipped to an external laboratory for testing without proper procedures being followed.

Smith also accused the company of misleading investors by overstating customer demand and manufacturing capacity.

After what he saw as more violations, Smith made an anonymous report to the Unilife board of directors alleging unethical activities, including stock fraud, suppression of negative information, compromise of the quality system and retaliation against whistleblowers. The latter charge related to Smith’s allegation that a reduction in workforce as a result of a lack of customer demand for Unilife products included many employees who had refused to participate in the company’s unlawful activities.

His supervisor was provided a copy of the allegations, and Smith ultimately was terminated.

Counterclaims

Unilife denied all of Smith’s allegations and filed counterclaims. The company accused him of secretly recording a conversation with Mojdeh in violation of the Pennsylvania Wire Tapping and Electronic Surveillance Control Act.

As part of the case’s dismissal, Smith has agreed to pay to settle Unilife’s claims against him.

The case, Talbot (Todd) Smith v. Unilife Corporation, Unilife Medical Solutions, Inc., Alan Shortall and Ramin Mojdeh, was filed in the U.S. District Court for the Eastern District of Pennsylvania. — Elizabeth Hollis

Regulatory Affairs Commercial Operations

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • AstraZeneca

    AstraZeneca Withdraws Imfinzi’s Bladder Cancer Indication

  • CE mark

    Cue Health’s COVID-19 Test Receives CE Mark

  • Sanofi-Regeneron_Logos.png

    Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

  • PerkinElmer logo

    PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing